Medical School · Year 3 · Psychiatry · includes a quiz and discussion video

Seminar 15: Psychopharmacology Principles

Psychiatry Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Apply pharmacokinetic principles of absorption, distribution, metabolism, and elimination to predict drug behavior and interactions in psychiatric practice
2. Describe the pharmacodynamic mechanisms of major psychotropic drug classes including receptor targets, time course of clinical effects, and dose-response relationships
3. Compare selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors by mechanism, clinical profile, and drug interaction potential
4. Evaluate the mechanisms, side-effect profiles, and metabolic monitoring requirements of first-generation and second-generation antipsychotic medications
5. Explain the pharmacology and monitoring requirements of mood stabilizers including lithium, valproate, and lamotrigine
6. Identify drug-drug interactions through CYP450 pathways and recognize the clinical features and management of serotonin syndrome

Seminar Outline

Section 1: Pharmacokinetic Principles

Absorption determines the rate and extent to which a drug reaches the systemic circulation and varies substantially across routes of administration in psychiatric practice. The oral route is used for the vast majority of psychiatric medications, with absorption occurring primarily in the small intestine and being influenced by gastric pH, motility, and the presence of food. First-pass hepatic metabolism significantly reduces the bioavailability of many orally administered psychotropics, with some agents such as chlorpromazine having oral bioavailability as low as thirty percent. Certain medications have specific food requirements: lurasidone must be taken with at least 350 calories to achieve adequate absorption, while other agents may have absorption impaired by antacids or dairy products. Intramuscular and intravenous routes bypass first-pass metabolism and provide more rapid onset, making them essential for acute situations such as severe agitation. Long-acting injectable formulations of antipsychotics such as paliperidone palmitate and aripiprazole lauroxil provide sustained drug delivery over weeks to months, improving adherence in patients with chronic psychotic disorders.

Distribution describes the movement of drug from the systemic circulation into body tissues and is governed by factors including lipophilicity, protein binding, and blood-brain barrier permeability. Most psychotropic medications are highly lipophilic, which facilitates their passage across the blood-brain barrier to reach central nervous system targets but also results in large volumes of distribution and prolonged tissue retention. Protein binding, primarily to albumin and alpha-1 acid glycoprotein, determines the fraction of drug that is pharmacologically active, as only unbound drug can cross membranes and interact with receptors. Changes in protein binding due to hepatic disease, malnutrition, or displacement by other highly bound drugs can alter free drug concentrations and produce unexpected toxicity or therapeutic failure. The volume of distribution is particularly large for many antipsychotic and antidepressant medications, which accumulate in adipose tissue and can produce prolonged effects even after discontinuation.

Metabolism of psychotropic medications occurs predominantly through hepatic cytochrome P450 enzymes, with CYP2D6, CYP3A4, CYP1A2, and CYP2C19 representing the most clinically relevant isoforms. CYP2D6 metabolizes numerous antidepressants and antipsychotics, and its activity is subject to significant genetic polymorphism, with poor metabolizers experiencing higher drug levels and extensive or ultra-rapid metabolizers requiring higher doses to achieve therapeutic concentrations. Enzyme inducers such as carbamazepine and cigarette smoking increase the activity of metabolic enzymes, accelerating the clearance of co-administered medications and potentially reducing their efficacy. Enzyme inhibitors such as fluoxetine and paroxetine, both potent CYP2D6 inhibitors, decrease the metabolism of co-administered substrates, increasing drug levels and the risk of toxicity. Phase II metabolism, including glucuronidation, acetylation, and sulfation, conjugates drug molecules for renal excretion and represents an alternative metabolic pathway that is less susceptible to drug interactions.

Elimination determines the duration of drug effect and the time required to achieve steady-state concentrations. The half-life of a drug, defined as the time required for the plasma concentration to decrease by fifty percent, governs dosing frequency and the time to steady state, which is achieved after approximately five half-lives. Fluoxetine has an exceptionally long half-life of two to six days, with its active metabolite norfluoxetine persisting for four to sixteen days, which provides a built-in taper effect but also means that drug interactions persist for weeks after discontinuation. Renal clearance is the primary elimination pathway for lithium and gabapentin, necessitating dose adjustment in the setting of renal impairment and making these agents susceptible to changes in renal function caused by dehydration, nonsteroidal anti-inflammatory drugs, or angiotensin-converting enzyme inhibitors. Hepatic impairment reduces the clearance of most psychotropic medications and may necessitate dose reduction, and clinicians must regularly assess hepatic and renal function to guide appropriate dosing adjustments.

<image>Panel A: Absorption pathways for psychiatric medications comparing oral bioavailability with first-pass metabolism, food effects, and parenteral routes including IM and long-acting injectable formulations. Panel B: Distribution factors affecting psychotropic drug delivery to the CNS including lipophilicity, protein binding, volume of distribution, and blood-brain barrier permeability. Panel C: CYP450 enzyme system showing major isoforms CYP2D6, CYP3A4, CYP1A2, and CYP2C19 with key inducers, inhibitors, and genetic polymorphism considerations. Panel D: Elimination principles showing half-life determination of dosing interval, steady-state achievement at five half-lives, and renal versus hepatic clearance pathways with dose adjustment requirements.</image>

Section 2: Pharmacodynamic Principles

Psychotropic medications exert their effects through interactions with specific neurotransmitter systems in the central nervous system. The serotonin system is the primary target of antidepressants used for depression, anxiety disorders, and obsessive-compulsive disorder. The norepinephrine system modulates alertness, energy, and mood, and is targeted by serotonin-norepinephrine reuptake inhibitors and tricyclic antidepressants. The dopamine system mediates reward, motivation, and motor function, and its dysregulation underlies both psychotic symptoms through mesolimbic hyperactivity and the negative symptoms and cognitive deficits of schizophrenia through mesocortical hypoactivity. Gamma-aminobutyric acid, the principal inhibitory neurotransmitter, is the target of benzodiazepines used for anxiety and insomnia. Glutamate, the principal excitatory neurotransmitter, has emerged as a target for novel antidepressants including ketamine. The cholinergic system plays roles in cognition and memory and is the target of cholinesterase inhibitors used in dementia treatment.

Drug-receptor interactions can be classified by the nature of the effect produced at the receptor level. Full agonists bind to and fully activate a receptor, producing a maximal response. Antagonists bind to a receptor without activating it, blocking the binding of endogenous neurotransmitters or other agonists. Partial agonists bind to and partially activate the receptor, producing a submaximal response that functionally stabilizes receptor activity, serving as an agonist in states of low endogenous neurotransmitter activity and as an antagonist when neurotransmitter activity is high; aripiprazole exemplifies this mechanism as a dopamine D2 partial agonist. Inverse agonists bind to constitutively active receptors and produce an effect opposite to that of an agonist. Reuptake inhibitors, the mechanism of SSRIs and SNRIs, block the presynaptic transporter protein that normally recycles neurotransmitter from the synapse, increasing the concentration and duration of neurotransmitter signaling in the synaptic cleft.

The temporal relationship between receptor-level pharmacology and clinical effect is a critical concept in psychiatric prescribing. Receptor occupancy and blockade of neurotransmitter reuptake begin within hours of the first dose, yet the clinical antidepressant or anxiolytic effect typically requires two to four weeks to manifest. This delay reflects the necessity of downstream neuroadaptive changes including receptor desensitization, changes in gene expression, increased neurotrophin production including brain-derived neurotrophic factor, and neuroplastic remodeling in mood-regulatory circuits. Tolerance may develop to certain drug effects, as occurs with the sedating properties of many antidepressants and the anxiolytic effects of benzodiazepines. Discontinuation syndromes can occur with abrupt cessation of medications that have produced neuroadaptive changes, with serotonin reuptake inhibitors producing flu-like symptoms, insomnia, and sensory disturbances, and benzodiazepines producing anxiety, insomnia, and in severe cases seizures.

The dose-response relationship in psychopharmacology is characterized by the therapeutic window, the range of drug concentrations that produces clinical benefit without unacceptable toxicity. Medications with narrow therapeutic indices, including lithium and tricyclic antidepressants, require careful dose titration and therapeutic drug monitoring because the margin between effective and toxic concentrations is small. Lithium's therapeutic range of 0.6 to 1.2 milliequivalents per liter lies close to the toxic range, and levels above 1.5 milliequivalents per liter produce significant toxicity. Medications with wide therapeutic indices, including SSRIs and most second-generation antipsychotics, provide greater dosing flexibility and a larger margin of safety in overdose. Individual variation in drug response, attributable to genetic polymorphisms in metabolic enzymes and drug targets, differences in body composition, and pharmacodynamic sensitivity, necessitates individualized dose titration guided by clinical response and tolerability rather than adherence to fixed-dose protocols.

<image>Panel A: Major neurotransmitter systems targeted by psychotropic medications showing serotonin, norepinephrine, dopamine, GABA, glutamate, and acetylcholine pathways with corresponding drug classes. Panel B: Drug-receptor interaction types including full agonist, antagonist, partial agonist, inverse agonist, and reuptake inhibitor mechanisms with graphical representation of receptor-level activity. Panel C: Timeline of pharmacological action showing immediate receptor occupancy versus delayed clinical response with intermediate neuroadaptive processes including receptor desensitization and neurotrophin changes. Panel D: Therapeutic window concept comparing narrow index medications such as lithium and TCAs with wide index medications such as SSRIs, showing relationship between dose, efficacy, and toxicity.</image>

Section 3: Antidepressant Overview

Antidepressant medications can be organized by their primary pharmacological mechanism of action, which determines both their therapeutic profile and side-effect patterns. Selective serotonin reuptake inhibitors block the serotonin transporter to increase serotonergic neurotransmission and are the most widely prescribed antidepressant class due to their favorable safety and tolerability profile. Serotonin-norepinephrine reuptake inhibitors block both the serotonin and norepinephrine transporters, providing dual monoamine enhancement that may offer advantages for certain symptom profiles including pain and fatigue. Tricyclic antidepressants inhibit the reuptake of serotonin and norepinephrine but also interact with histaminic, cholinergic, and alpha-adrenergic receptors, producing a broad side-effect profile and significant toxicity in overdose. Monoamine oxidase inhibitors block the enzyme responsible for degrading monoamine neurotransmitters, producing a global increase in serotonin, norepinephrine, and dopamine. Atypical antidepressants encompass agents with diverse mechanisms that do not fit neatly into the above categories.

The six SSRIs share their primary mechanism but differ meaningfully in pharmacokinetic properties, drug interaction profiles, and secondary pharmacological effects. Fluoxetine has the longest half-life of the class, which provides protection against missed-dose effects and discontinuation symptoms but also means that drug interactions and side effects persist for weeks after discontinuation; it is also a potent CYP2D6 inhibitor. Sertraline has fewer drug interactions than most SSRIs and is the agent with the strongest evidence base in post-myocardial infarction depression, though gastrointestinal side effects are common at initiation. Paroxetine is the most sedating and anticholinergic SSRI, is a potent CYP2D6 inhibitor, has the most severe discontinuation syndrome of the class, and is associated with an increased risk of cardiac defects when used in the first trimester of pregnancy. Citalopram is associated with dose-dependent QTc prolongation, prompting a maximum recommended dose of forty milligrams. Escitalopram, the S-enantiomer of citalopram, is generally well tolerated with a clean drug interaction profile. Fluvoxamine is primarily used for obsessive-compulsive disorder and is a potent inhibitor of CYP1A2 and CYP2C19.

The SNRIs provide combined serotonin and norepinephrine reuptake inhibition, with the norepinephrine component becoming clinically relevant at higher doses for some agents. Venlafaxine exhibits dose-dependent pharmacology, functioning primarily as a serotonin reuptake inhibitor at lower doses and recruiting significant norepinephrine reuptake inhibition at doses above 150 milligrams; it can produce blood pressure elevation at higher doses and has a significant discontinuation syndrome due to its short half-life. Desvenlafaxine is the active metabolite of venlafaxine and offers a simpler pharmacokinetic profile with fewer drug interactions and more predictable dosing. Duloxetine is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain, making it particularly useful for patients with comorbid pain conditions; hepatotoxicity is a concern in patients with pre-existing liver disease. Levomilnacipran has a greater selectivity for norepinephrine over serotonin reuptake inhibition, which may offer advantages for symptoms of fatigue and cognitive dulling.

The selection of an antidepressant for a given patient integrates multiple clinical considerations. Prior response to a specific medication is among the strongest predictors of future response and should guide initial selection. Family members' medication responses may also predict individual response, reflecting shared pharmacogenomic profiles. The side-effect profile should be matched to the patient's symptom burden: a sedating agent may benefit the patient with insomnia, while an activating agent may be preferred for the patient with fatigue and hypersomnia. Medical comorbidities influence selection, as duloxetine may address both depression and chronic pain, while bupropion may be preferred when sexual dysfunction from serotonergic agents is problematic. Drug interaction potential must be carefully assessed, particularly in patients taking multiple medications. Practical factors including cost, insurance formulary coverage, and available formulations should not be overlooked, as they directly influence adherence and treatment outcomes.

<image>Panel A: Antidepressant mechanism classes showing SSRIs, SNRIs, TCAs, MAOIs, and atypical agents with their primary pharmacological targets and relative clinical positioning. Panel B: SSRI comparative pharmacology showing fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine with half-lives, CYP interactions, and distinguishing clinical features. Panel C: SNRI pharmacology showing venlafaxine dose-dependent norepinephrine recruitment, desvenlafaxine simplified kinetics, duloxetine pain indications, and levomilnacipran norepinephrine selectivity. Panel D: Antidepressant selection algorithm incorporating prior response, family history, side-effect matching, comorbidity considerations, drug interactions, and practical factors.</image>

Section 4: Other Antidepressants

Tricyclic antidepressants were the dominant antidepressant class before the introduction of SSRIs and remain clinically relevant for specific indications despite their unfavorable safety profile. Amitriptyline is the most sedating TCA and is commonly used off-label for chronic pain and migraine prophylaxis, though its anticholinergic effects and weight gain limit tolerability. Nortriptyline, the active metabolite of amitriptyline, is less anticholinergic and better tolerated, with established efficacy for neuropathic pain and depression. Imipramine, the first TCA introduced, retains a role in the treatment of nocturnal enuresis in children. Clomipramine is the most serotonergic TCA and is the most effective medication for obsessive-compulsive disorder among this class. The shared side effects of TCAs include anticholinergic effects encompassing dry mouth, constipation, urinary retention, and blurred vision; cardiac conduction abnormalities including QTc prolongation and increased risk of arrhythmia; orthostatic hypotension; sedation; and lethality in overdose, with as little as a one-week supply potentially fatal. Electrocardiographic monitoring and therapeutic drug level monitoring are recommended during treatment.

Monoamine oxidase inhibitors represent the oldest class of antidepressants and are among the most effective, but their use is restricted by serious dietary and drug interaction requirements. Phenelzine and tranylcypromine are irreversible, non-selective inhibitors of both MAO-A and MAO-B that require strict avoidance of tyramine-containing foods including aged cheeses, cured meats, fermented products, and certain beverages. Failure to follow the tyramine-restricted diet can produce a hypertensive crisis with severe headache, hypertension, and potential intracranial hemorrhage. Selegiline is available as a transdermal patch that, at the lowest dose, provides selective MAO-B inhibition at the brain level while preserving sufficient intestinal MAO-A activity to metabolize dietary tyramine, reducing dietary restrictions. Drug interactions with serotonergic medications are potentially fatal, and a washout period of at least two weeks, or five weeks for fluoxetine, must be observed when transitioning between MAOIs and serotonergic antidepressants. Despite these limitations, MAOIs remain important options for treatment-resistant depression and atypical depression characterized by hypersomnia, hyperphagia, leaden paralysis, and rejection sensitivity.

Atypical antidepressants encompass several pharmacologically diverse agents that offer distinct clinical profiles. Bupropion inhibits the reuptake of norepinephrine and dopamine without affecting serotonin, resulting in an activating profile with no sexual dysfunction and no weight gain; however, it lowers the seizure threshold in a dose-dependent manner and is contraindicated in patients with seizure disorders, eating disorders, or those undergoing abrupt discontinuation of alcohol or benzodiazepines. Mirtazapine antagonizes alpha-2 adrenergic autoreceptors, increasing norepinephrine and serotonin release, and also blocks serotonin 5-HT2 and 5-HT3 receptors and histamine H1 receptors, producing a profile characterized by significant sedation, appetite stimulation, and weight gain that can be therapeutically leveraged in patients with insomnia and poor appetite. Trazodone is a serotonin antagonist and reuptake inhibitor used primarily at low doses as a sleep aid, with priapism as a rare but serious adverse effect. Vilazodone combines serotonin reuptake inhibition with 5-HT1A partial agonism, and vortioxetine acts through a multimodal serotonergic mechanism with emerging evidence for cognitive benefits in depression.

Ketamine and its S-enantiomer esketamine represent a paradigm shift in antidepressant pharmacology through their action as N-methyl-D-aspartate receptor antagonists. Esketamine is FDA-approved as a nasal spray for treatment-resistant depression, defined as failure to respond to at least two adequate antidepressant trials, and for major depressive disorder with acute suicidal ideation or behavior. The most remarkable feature of ketamine-based therapy is the rapidity of antidepressant response, with significant symptom improvement occurring within hours to days rather than the weeks required by conventional antidepressants. The mechanism involves NMDA receptor blockade leading to a surge in glutamate release, activation of AMPA receptors, increased brain-derived neurotrophic factor signaling, and rapid synaptogenesis in prefrontal cortical and hippocampal circuits. Esketamine is administered under a Risk Evaluation and Mitigation Strategy program that requires administration at certified healthcare facilities with observation for at least two hours afterward, due to the risks of dissociation, sedation, and transient blood pressure elevation.

<image>Panel A: Tricyclic antidepressant pharmacology showing amitriptyline, nortriptyline, imipramine, and clomipramine with receptor binding profiles, clinical uses, shared side effects, and overdose lethality. Panel B: MAOI pharmacology showing phenelzine, tranylcypromine, and selegiline patch with dietary tyramine restriction requirements, hypertensive crisis risk, and drug interaction washout periods. Panel C: Atypical antidepressant mechanisms showing bupropion norepinephrine-dopamine activity, mirtazapine receptor profile, trazodone serotonin antagonism, and multimodal agents vilazodone and vortioxetine. Panel D: Ketamine and esketamine mechanism of action showing NMDA antagonism, rapid glutamatergic cascade, synaptogenesis pathway, clinical response timeline, and REMS program requirements.</image>

Section 5: Antipsychotic Mechanisms

The dopamine hypothesis of schizophrenia provides the foundational framework for understanding antipsychotic pharmacology. Positive symptoms including hallucinations, delusions, and disorganized thinking are attributed to excessive dopaminergic activity in the mesolimbic pathway projecting from the ventral tegmental area to limbic structures. Negative symptoms including flat affect, avolition, alogia, and social withdrawal are conceptualized as resulting from reduced dopaminergic activity in the mesocortical pathway projecting to the prefrontal cortex. The therapeutic effect of all antipsychotic medications correlates with their degree of dopamine D2 receptor blockade, with optimal efficacy achieved at sixty-five to eighty percent receptor occupancy in the striatum. Occupancy exceeding eighty percent is associated with the emergence of extrapyramidal symptoms, establishing a therapeutic window for D2 blockade that guides dosing.

First-generation antipsychotics, also termed typical or conventional antipsychotics, primarily achieve their therapeutic effect through potent D2 receptor antagonism with relatively little activity at other receptor systems. High-potency agents such as haloperidol and fluphenazine provide effective antipsychotic activity but carry a substantial risk of extrapyramidal symptoms including akathisia, dystonia, parkinsonism, and tardive dyskinesia, owing to their high D2 occupancy in the nigrostriatal pathway. Medium-potency agents such as perphenazine offer a moderate balance between antipsychotic efficacy and side effects. Low-potency agents such as chlorpromazine produce less extrapyramidal effects but more sedation, orthostatic hypotension, and anticholinergic effects due to their broader receptor binding profile. Despite the introduction of second-generation agents, first-generation antipsychotics remain widely used due to their proven efficacy, availability in long-acting injectable formulations, and lower cost.

Second-generation antipsychotics, also termed atypical antipsychotics, were developed to provide antipsychotic efficacy with reduced extrapyramidal risk, primarily through the addition of serotonin 5-HT2A receptor antagonism to D2 blockade. Risperidone provides effective antipsychotic activity but can produce extrapyramidal symptoms and hyperprolactinemia at higher doses due to its relatively tight D2 binding. Olanzapine is among the most effective antipsychotics but causes significant weight gain and metabolic disturbance including hyperglycemia and dyslipidemia. Quetiapine is highly sedating and has relatively low extrapyramidal risk but also produces metabolic effects. Aripiprazole functions as a dopamine D2 partial agonist, providing antipsychotic activity while producing less metabolic disturbance and no prolactin elevation; it may cause akathisia. Ziprasidone is weight-neutral but carries a risk of QTc prolongation. Lurasidone requires administration with food and has a favorable metabolic profile. Clozapine is the most effective antipsychotic, uniquely efficacious for treatment-resistant schizophrenia, but is reserved due to the risk of agranulocytosis requiring mandatory hematological monitoring.

The expanding roster of newer antipsychotic agents reflects ongoing efforts to optimize the efficacy-tolerability balance. Paliperidone, the active metabolite of risperidone, is available in oral and long-acting injectable formulations and undergoes primarily renal elimination, reducing hepatic drug interaction potential. Cariprazine, a dopamine D3-preferring partial agonist, has shown particular promise for negative symptoms of schizophrenia. Brexpiprazole, another partial agonist, is approved both for schizophrenia and as adjunctive treatment for major depressive disorder. Lumateperone achieves antipsychotic efficacy at remarkably low D2 occupancy and demonstrates a metabolically neutral profile. Pimavanserin, a selective serotonin 5-HT2A inverse agonist without D2 activity, is approved specifically for hallucinations and delusions associated with Parkinson disease psychosis, representing a niche mechanism that avoids dopaminergic side effects in this vulnerable population.

<image>Panel A: Dopamine hypothesis of schizophrenia showing mesolimbic hyperactivity producing positive symptoms, mesocortical hypoactivity producing negative symptoms, and the D2 occupancy therapeutic window of sixty-five to eighty percent. Panel B: First-generation antipsychotic potency spectrum from high-potency haloperidol through medium perphenazine to low-potency chlorpromazine with corresponding side-effect profiles. Panel C: Second-generation antipsychotic comparison showing risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, lurasidone, and clozapine with key clinical features and metabolic risk profiles. Panel D: Newer antipsychotic mechanisms including paliperidone renal clearance, cariprazine D3 preference for negative symptoms, lumateperone low D2 occupancy, and pimavanserin selective 5-HT2A activity for Parkinson psychosis.</image>

Section 6: Mood Stabilizers

Lithium remains the cornerstone of bipolar disorder pharmacotherapy despite being one of the oldest agents in the psychiatric formulary. Its mechanism of action is incompletely understood but involves modulation of intracellular signaling cascades including inhibition of glycogen synthase kinase-3 beta and inositol monophosphatase, effects on neurotrophic pathways, and neuroprotective properties that may underlie its unique anti-suicidal effect. The therapeutic range for acute mania is 0.8 to 1.2 milliequivalents per liter, while maintenance therapy typically targets 0.6 to 1.0 milliequivalents per liter. Common side effects include fine tremor, polyuria and polydipsia from nephrogenic diabetes insipidus, hypothyroidism in approximately twenty percent of patients, weight gain, and cognitive dulling. Lithium toxicity, which can occur at levels above 1.5 milliequivalents per liter, manifests as coarse tremor, ataxia, confusion, dysarthria, and in severe cases seizures, coma, and death. Monitoring includes regular lithium levels, renal function, and thyroid function, and patients must be counseled about the risk factors for toxicity including dehydration, nonsteroidal anti-inflammatory drugs, and angiotensin-converting enzyme inhibitors.

The anticonvulsant mood stabilizers expand the pharmacological options for bipolar disorder, each with distinct efficacy profiles and safety considerations. Valproate, available as valproic acid and divalproex sodium, is effective for acute mania and has a broader spectrum of efficacy than some alternatives; its therapeutic range is 50 to 125 micrograms per milliliter, and side effects include weight gain, tremor, hair loss, hepatotoxicity requiring liver function monitoring, and thrombocytopenia. Carbamazepine is effective for acute mania and mixed episodes and acts as a potent inducer of multiple CYP450 enzymes, complicating co-administration with other medications; HLA-B*1502 testing is recommended in patients of Asian ancestry due to the risk of Stevens-Johnson syndrome. Lamotrigine has demonstrated particular efficacy in the prevention of bipolar depressive episodes and is the only mood stabilizer with stronger evidence for depression prevention than mania prevention. Oxcarbazepine is used as an alternative to carbamazepine with fewer drug interactions but carries a risk of hyponatremia.

Valproate warrants particular attention due to its unique risk-benefit profile and contraindications. The therapeutic range of 50 to 125 micrograms per milliliter is targeted for mood stabilization, with loading strategies available for acute mania. The metabolic side effects of weight gain and insulin resistance are clinically significant and contribute to cardiovascular risk. Hepatotoxicity, while rare in adults, necessitates baseline and periodic monitoring of liver function tests, and the drug should be used cautiously in patients with pre-existing hepatic disease. The most critical safety concern is teratogenicity: valproate is associated with a dose-dependent risk of neural tube defects, craniofacial abnormalities, and neurodevelopmental impairment in offspring, with estimated rates of major malformations approaching ten percent, making it an absolute contraindication in women who are pregnant or planning pregnancy. An association with polycystic ovarian syndrome has been reported in women of reproductive age, further limiting its use in this population.

Lamotrigine occupies a unique position among mood stabilizers due to its efficacy in bipolar depression prevention and its distinct safety profile. Unlike lithium and valproate, lamotrigine has not demonstrated robust efficacy for acute mania but excels in the prevention of depressive recurrence, which constitutes the predominant mood polarity and greatest source of disability in many bipolar patients. The most important prescribing consideration is the requirement for extremely slow dose titration to minimize the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. The recommended starting dose is twenty-five milligrams daily for the first two weeks, followed by a gradual increase to a target dose of typically 200 milligrams daily over six or more weeks. When lamotrigine is co-administered with valproate, which inhibits lamotrigine's glucuronide conjugation, the starting dose must be halved and the titration schedule lengthened further. The risk of serious rash is greatest during the first eight weeks of therapy and is increased by rapid dose escalation, concurrent valproate use, and younger age.

<image>Panel A: Lithium pharmacology showing proposed mechanisms of action, therapeutic ranges for acute mania and maintenance, common side effects, toxicity levels and manifestations, and required monitoring parameters. Panel B: Anticonvulsant mood stabilizers comparing valproate, carbamazepine, lamotrigine, and oxcarbazepine across efficacy profiles, therapeutic ranges, CYP interactions, and key safety concerns. Panel C: Valproate risk-benefit analysis showing metabolic effects, hepatotoxicity monitoring, teratogenicity risk quantification with neural tube defect rates, and absolute pregnancy contraindication. Panel D: Lamotrigine titration protocol showing starting doses with and without valproate, weekly dose escalation schedule, target dose range, and Stevens-Johnson syndrome risk factors and timeline.</image>

Section 7: Anxiolytics and Sedative-Hypnotics

Benzodiazepines enhance the function of gamma-aminobutyric acid at the GABA-A receptor by binding to an allosteric site that increases the frequency of chloride channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects. Alprazolam is a short-acting, high-potency benzodiazepine widely used for panic disorder but carries the highest dependence risk and most severe discontinuation syndrome of the class. Lorazepam has an intermediate half-life, no active metabolites, and undergoes glucuronidation rather than oxidative hepatic metabolism, making it the preferred benzodiazepine in patients with hepatic impairment and in acute medical settings. Clonazepam has a long half-life that provides sustained anxiolysis with less interdose rebound but requires more time to clear after discontinuation. Diazepam has a long half-life and multiple active metabolites that can accumulate, particularly in elderly patients and those with hepatic impairment. All benzodiazepines carry risks of physical and psychological dependence, tolerance, cognitive impairment, psychomotor slowing, and increased fall risk, particularly in older adults.

The clinical selection of benzodiazepines is guided by the specific indication, required onset and duration of action, and patient-specific safety factors. For panic disorder, high-potency agents such as alprazolam and clonazepam are most effective, with clonazepam's longer half-life offering more sustained coverage with fewer interdose fluctuations. For generalized anxiety disorder, longer-acting agents provide more consistent anxiolysis. For insomnia, shorter-acting agents are preferred to minimize next-day sedation. In alcohol withdrawal, long-acting agents such as diazepam or chlordiazepoxide are favored because their gradual decline in plasma levels provides a smoother withdrawal trajectory, and dosing can be guided by the Clinical Institute Withdrawal Assessment for Alcohol scale. In elderly patients, benzodiazepines should be avoided whenever possible due to increased sensitivity, the risk of falls and hip fractures, and cognitive effects that may mimic or worsen dementia; when absolutely necessary, short-acting agents at the lowest effective dose are recommended.

Non-benzodiazepine anxiolytics offer alternatives that avoid the dependence and cognitive risks associated with benzodiazepines. Buspirone is a serotonin 5-HT1A partial agonist approved for generalized anxiety disorder that has no sedative, muscle relaxant, or anticonvulsant properties, no abuse potential, and no discontinuation syndrome; however, it requires consistent daily dosing for two to four weeks before therapeutic effects emerge, which limits its utility for acute anxiety. Hydroxyzine, a first-generation antihistamine, provides rapid anxiolysis through histamine H1 receptor antagonism and can be used on an as-needed basis but produces sedation and anticholinergic effects. Gabapentin and pregabalin, alpha-2-delta calcium channel ligands, are increasingly used off-label for anxiety and have demonstrated efficacy in generalized anxiety disorder and social anxiety disorder, though gabapentin has emerging evidence of abuse potential in certain populations. Beta-adrenergic blockers, particularly propranolol, are effective for performance anxiety by blocking the peripheral sympathetic manifestations of anxiety including tachycardia, tremor, and diaphoresis without affecting cognitive anxious processes.

The Z-drugs, comprising zolpidem, zaleplon, and eszopiclone, were designed to provide hypnotic efficacy through selective binding to the alpha-1 subunit of the GABA-A receptor while minimizing the anxiolytic, anticonvulsant, and muscle relaxant effects of benzodiazepines. Zolpidem is available in multiple formulations and is effective for sleep-onset insomnia, though lower doses are recommended in women due to slower metabolism. Zaleplon has an ultra-short duration suitable for middle-of-the-night awakening when at least four hours of sleep time remain. Eszopiclone has a longer duration that addresses both sleep-onset and sleep-maintenance insomnia. Despite their selectivity, Z-drugs share important risks with benzodiazepines including the development of tolerance and dependence with chronic use, and the FDA has mandated a black box warning regarding the risk of complex sleep behaviors including sleepwalking, sleep-driving, and sleep-eating that have resulted in serious injuries and deaths. These medications should be prescribed with the same caution regarding duration, dose, and patient selection as traditional benzodiazepines.

<image>Panel A: Benzodiazepine pharmacology showing GABA-A receptor allosteric mechanism, comparison of alprazolam, lorazepam, clonazepam, and diazepam across potency, half-life, metabolism, and active metabolite profiles. Panel B: Clinical benzodiazepine selection guide organized by indication including panic disorder, generalized anxiety, insomnia, and alcohol withdrawal with agent recommendations and elderly precautions. Panel C: Non-benzodiazepine anxiolytics showing buspirone 5-HT1A mechanism with delayed onset, hydroxyzine antihistamine action, gabapentin and pregabalin alpha-2-delta binding, and propranolol peripheral sympatholysis for performance anxiety. Panel D: Z-drug pharmacology showing alpha-1 GABA-A selectivity, formulation differences, gender-based dosing for zolpidem, and FDA black box warning for complex sleep behaviors.</image>

Section 8: Common Side Effects

Antidepressant side effects are among the most frequent reasons for treatment discontinuation and require proactive management. Sexual dysfunction, including decreased libido, anorgasmia, and erectile dysfunction, affects thirty to seventy percent of patients taking serotonergic antidepressants and is the most common reason for non-adherence. Management strategies include waiting for tolerance to develop, dose reduction, switching to a non-serotonergic agent such as bupropion or mirtazapine, or adding bupropion as an adjunct. Weight gain occurs with several antidepressants, most notably mirtazapine and paroxetine, and requires monitoring and lifestyle intervention. Gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort are common during the first one to two weeks of SSRI therapy and typically improve with continued treatment; taking medication with food can mitigate symptoms during this initial period. Insomnia or sedation can be managed by adjusting the timing of dosing, with activating agents taken in the morning and sedating agents taken at bedtime. Discontinuation syndrome, characterized by flu-like symptoms, insomnia, sensory disturbances, and irritability, can be minimized by gradual tapering over several weeks.

Antipsychotic side effects carry significant metabolic, neurological, and endocrine consequences that necessitate systematic monitoring. Weight gain and metabolic syndrome, encompassing hyperglycemia, dyslipidemia, and central obesity, are the most impactful long-term side effects and are most pronounced with olanzapine and clozapine; baseline and periodic monitoring of weight, fasting glucose, lipid panel, and waist circumference is required. Extrapyramidal symptoms include acute dystonia, which can be treated with diphenhydramine or benztropine; akathisia, which may respond to dose reduction, beta-blockers, or benzodiazepines; and drug-induced parkinsonism, which may require dose reduction or anticholinergic medication. Tardive dyskinesia, a potentially irreversible movement disorder of late onset, is treated with vesicular monoamine transporter-2 inhibitors including valbenazine and deutetrabenazine, or by switching to a lower-risk agent. Hyperprolactinemia, caused by D2 blockade in the tuberoinfundibular pathway, can produce galactorrhea, amenorrhea, sexual dysfunction, and long-term osteoporosis risk; switching to aripiprazole or quetiapine often resolves symptoms.

Mood stabilizer side effects require specific monitoring protocols depending on the agent. Lithium-induced tremor, most commonly a fine postural tremor of the hands, can be managed with dose reduction or the addition of a low-dose beta-blocker such as propranolol. Polyuria and polydipsia result from lithium-induced nephrogenic diabetes insipidus and may be managed with amiloride, a potassium-sparing diuretic, while monitoring renal function. Hypothyroidism develops in approximately twenty percent of patients on chronic lithium therapy and is managed with levothyroxine replacement. Lithium-induced weight gain, averaging four to ten kilograms, requires lifestyle intervention and monitoring. Cognitive dulling, often described by patients as a blunting of mental sharpness, may improve with dose reduction but can be a significant quality-of-life concern. For valproate, the key monitoring targets include liver function tests for hepatotoxicity, complete blood count for thrombocytopenia, and weight and metabolic parameters. For lamotrigine, any rash during the titration period must be evaluated for the possibility of Stevens-Johnson syndrome.

Serotonin syndrome represents a potentially life-threatening pharmacological emergency resulting from excessive serotonergic activity in the central nervous system. The clinical triad encompasses mental status changes including agitation, confusion, and hypomania; autonomic instability including hyperthermia, tachycardia, diaphoresis, and labile blood pressure; and neuromuscular abnormalities including clonus, hyperreflexia, tremor, and rigidity. The neuromuscular findings, particularly lower extremity clonus and hyperreflexia, are the most diagnostically useful features and help distinguish serotonin syndrome from neuroleptic malignant syndrome. The most common precipitants are combinations of serotonergic medications, with the combination of a monoamine oxidase inhibitor and a serotonin reuptake inhibitor being the most dangerous; other common combinations include SSRIs with tramadol, SSRIs with triptans, and polypharmacy involving multiple serotonergic agents. Management requires immediate discontinuation of all serotonergic medications, supportive care with intravenous fluids and cooling measures, benzodiazepines for agitation and seizures, and cyproheptadine, a serotonin antagonist, administered as a twelve-milligram loading dose followed by two milligrams every two hours as needed. Prevention through awareness of serotonergic drug interactions is the most effective strategy.

<image>Panel A: Antidepressant side effects showing sexual dysfunction prevalence and management, weight gain by agent, gastrointestinal symptom timeline, and discontinuation syndrome prevention through tapering. Panel B: Antipsychotic metabolic monitoring protocol showing weight, glucose, lipids, and waist circumference measurement schedule with high-risk agents identified and tardive dyskinesia treatment with VMAT2 inhibitors. Panel C: Lithium side-effect management showing tremor treatment with beta-blockers, nephrogenic diabetes insipidus management with amiloride, hypothyroidism replacement, and cognitive dulling dose adjustment. Panel D: Serotonin syndrome clinical triad showing mental status, autonomic, and neuromuscular features with precipitant drug combinations, differentiation from NMS, and stepwise management with cyproheptadine.</image>

Section 9: Drug Interactions

CYP2D6 interactions are among the most clinically significant in psychopharmacology due to the large number of psychotropic substrates metabolized by this enzyme and the potent inhibition produced by several commonly prescribed agents. Fluoxetine, paroxetine, and bupropion are potent CYP2D6 inhibitors that can significantly increase the plasma concentrations of co-administered substrates. Important CYP2D6 substrates include risperidone, aripiprazole, haloperidol, and atomoxetine, all of which may reach toxic levels when co-administered with a potent inhibitor. Codeine requires CYP2D6 for conversion to its active metabolite morphine, and concurrent use of a CYP2D6 inhibitor effectively blocks this activation, rendering codeine ineffective for pain relief. Pharmacogenomic testing for CYP2D6 can identify poor metabolizers who behave as if constitutively inhibited and ultra-rapid metabolizers who clear drugs faster than expected, informing dose adjustments for affected medications.

CYP3A4 interactions affect a broad range of psychotropic medications because this enzyme metabolizes approximately fifty percent of all pharmaceuticals. Potent inducers including carbamazepine, phenytoin, and rifampin dramatically increase CYP3A4 activity, reducing plasma levels of substrates including many benzodiazepines, quetiapine, lurasidone, and hormonal contraceptives, potentially compromising their efficacy. Potent inhibitors including ketoconazole, erythromycin, and certain protease inhibitors decrease CYP3A4 activity, increasing substrate levels and the risk of toxicity. Fluvoxamine is a notable psychiatric medication that inhibits both CYP1A2 and CYP3A4, producing clinically significant interactions with multiple co-administered drugs. Grapefruit juice inhibits intestinal CYP3A4 and can increase the bioavailability of orally administered substrates. The clinical impact of CYP3A4 interactions is particularly relevant for patients taking anticonvulsant mood stabilizers concurrently with antipsychotics or benzodiazepines.

Beyond cytochrome P450 interactions, several other drug combinations in psychiatric practice carry high-risk profiles. The combination of a monoamine oxidase inhibitor with any serotonergic medication is the most dangerous drug interaction in psychiatry and can produce fatal serotonin syndrome. Lithium toxicity can be precipitated by nonsteroidal anti-inflammatory drugs, which reduce renal lithium clearance, and by angiotensin-converting enzyme inhibitors and thiazide diuretics, which alter renal handling of lithium. The combination of clozapine with carbamazepine is contraindicated due to the additive risk of agranulocytosis. QTc-prolonging drug combinations increase the risk of torsades de pointes and sudden cardiac death, and clinicians must be vigilant when prescribing multiple agents with QTc-prolonging potential including certain antipsychotics, antidepressants, and antibiotics. Pharmacokinetic interactions between immunosuppressants and psychotropics are particularly important in transplant psychiatry.

Systematic approaches to identifying and managing drug interactions are essential components of safe prescribing practice. Electronic drug interaction databases including Lexicomp, Epocrates, and Clinical Pharmacology should be consulted when adding any new medication to a patient's regimen, and many electronic health record systems incorporate automated interaction alerts. The scope of interaction checking must extend beyond prescription medications to include over-the-counter preparations, herbal supplements such as St. John's wort, which is a potent CYP3A4 inducer and serotonergic agent, and recreational substances. When clinically significant interactions are identified, management options include selecting an alternative medication without the interaction, adjusting doses to compensate for the altered pharmacokinetics, and increasing monitoring of drug levels or clinical parameters. The rationale for proceeding with a known interaction, when the clinical benefit is judged to outweigh the risk, should be clearly documented in the medical record.

<image>Panel A: CYP2D6 interaction map showing potent inhibitors fluoxetine, paroxetine, and bupropion connected to major substrates including risperidone, aripiprazole, haloperidol, and atomoxetine with clinical consequences. Panel B: CYP3A4 interaction map showing inducers carbamazepine, phenytoin, and rifampin and inhibitors ketoconazole and fluvoxamine with effects on benzodiazepine, quetiapine, and lurasidone levels. Panel C: High-risk drug combinations in psychiatry including MAOI plus serotonergic agents, lithium with NSAIDs and ACE inhibitors, clozapine with carbamazepine, and QTc-prolonging combinations with clinical consequences. Panel D: Systematic interaction checking workflow showing electronic database resources, expanded scope to include OTC and supplements, management options for identified interactions, and documentation requirements.</image>

Section 10: Special Populations

Prescribing psychotropic medications during pregnancy and lactation requires careful weighing of the risks of medication exposure against the risks of untreated maternal psychiatric illness. Most SSRIs are considered relatively safer options during pregnancy, with sertraline and escitalopram having the most reassuring data, while paroxetine should be avoided in the first trimester due to an association with cardiac malformations. Valproate is absolutely contraindicated in pregnancy due to the high risk of neural tube defects, craniofacial anomalies, and neurodevelopmental impairment. Lithium carries a risk of Ebstein anomaly, though the absolute risk is lower than historically estimated at approximately 0.1 percent, and it may be continued in pregnancy when the clinical need is compelling and the patient is fully informed. Antipsychotic medications are generally continued when indicated, with consideration of potential metabolic effects on the pregnancy. Many psychotropic medications are compatible with breastfeeding, with sertraline and paroxetine having the lowest breast milk transfer rates among the SSRIs.

Psychopharmacology in elderly patients is complicated by age-related physiological changes that alter drug handling and increase vulnerability to adverse effects. The principle of starting at low doses and titrating slowly acknowledges the reduced hepatic and renal clearance, altered body composition with increased adipose tissue and decreased lean body mass, and increased sensitivity to central nervous system effects that characterize aging. Anticholinergic medications should be avoided in elderly patients due to their association with cognitive impairment, confusion, falls, urinary retention, and constipation. Benzodiazepines are listed on the American Geriatrics Society Beers Criteria as potentially inappropriate medications in older adults due to increased risk of cognitive impairment, delirium, falls, and hip fractures. Polypharmacy is common in elderly patients and increases the risk of drug-drug interactions, necessitating regular medication reconciliation and simplification when possible.

Hepatic impairment alters the metabolism of the majority of psychotropic medications and requires systematic dose adjustment. Drugs that undergo extensive hepatic metabolism, including most antidepressants, antipsychotics, and benzodiazepines, will have prolonged half-lives and elevated plasma concentrations in the setting of hepatic dysfunction. Potentially hepatotoxic medications including valproate and duloxetine should be avoided or used with extreme caution in patients with liver disease. Sedating medications require particular caution because hepatic encephalopathy reduces the threshold for central nervous system depression. Lorazepam, oxazepam, and temazepam are preferred benzodiazepines in hepatic impairment because they undergo glucuronidation rather than oxidative metabolism and do not produce active metabolites, providing more predictable pharmacokinetics independent of hepatic function.

Renal impairment primarily affects medications that undergo significant renal clearance, with lithium being the most important psychotropic in this category. Lithium is almost entirely eliminated by the kidneys, and any reduction in glomerular filtration rate, whether from chronic kidney disease, acute kidney injury, dehydration, or medications that reduce renal blood flow, increases the risk of lithium accumulation and toxicity. Dose reduction and more frequent monitoring of lithium levels are required in the setting of renal impairment. Gabapentin and pregabalin are also renally cleared and require dose adjustment based on creatinine clearance. Paliperidone undergoes predominantly renal elimination, distinguishing it from other atypical antipsychotics, and requires dose reduction in patients with reduced kidney function. Most other psychotropic medications are primarily hepatically metabolized and are less affected by renal impairment, though active metabolites of some agents may accumulate when renal clearance is reduced.

<image>Panel A: Pregnancy psychopharmacology showing SSRI safety hierarchy, valproate absolute contraindication with teratogenicity data, lithium Ebstein anomaly risk quantification, and breastfeeding compatibility ratings. Panel B: Geriatric prescribing principles showing physiological changes affecting drug handling, anticholinergic avoidance rationale, Beers Criteria benzodiazepine caution, and polypharmacy management. Panel C: Hepatic impairment considerations showing dose adjustment for hepatically metabolized drugs, hepatotoxic medication avoidance, sedation threshold in encephalopathy, and preferred benzodiazepines with glucuronidation pathway. Panel D: Renal impairment effects on lithium clearance with dose reduction and monitoring requirements, gabapentin and paliperidone dose adjustment by creatinine clearance, and general principles for renally versus hepatically cleared psychotropics.</image>

Summary

• CYP450 enzymes, particularly CYP2D6, CYP3A4, CYP1A2, and CYP2C19, mediate the majority of psychotropic drug metabolism and are the primary source of drug-drug interactions
• SSRIs differ in half-life, CYP inhibition profile, and secondary pharmacological effects despite sharing their primary serotonin reuptake mechanism
• SNRIs add norepinephrine reuptake inhibition and may benefit patients with comorbid pain, with venlafaxine producing dose-dependent blood pressure elevation at higher doses
• TCAs interact with multiple receptor systems producing anticholinergic, cardiac, and sedative effects, and have a narrow therapeutic index with lethality in overdose
• Antipsychotics achieve efficacy through D2 blockade, with second-generation agents adding 5-HT2A antagonism and requiring metabolic monitoring for weight gain, hyperglycemia, and dyslipidemia
• Lithium has a narrow therapeutic index of 0.6 to 1.2 milliequivalents per liter requiring regular monitoring of levels, renal function, and thyroid function
• Valproate is absolutely contraindicated in pregnancy due to neural tube defects, hepatotoxicity requires liver function monitoring, and weight gain is a significant clinical concern
• Lamotrigine requires slow dose titration over six or more weeks to minimize Stevens-Johnson syndrome risk and is uniquely effective for bipolar depression prevention
• Benzodiazepines produce dependence and cognitive impairment and should be avoided in elderly patients per the Beers Criteria
• Serotonin syndrome presents with mental status changes, autonomic instability, and neuromuscular hyperactivity and is treated by discontinuing serotonergic agents, supportive care, and cyproheptadine

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown